Eledon Pharmaceuticals
ELDN
31 hedge funds and large institutions have $15.9M invested in Eledon Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
1.46% less ownership
Funds ownership: 48.95% → 47.49% (-1.5%)
3% less funds holding
Funds holding: 32 → 31 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
42% less capital invested
Capital invested by funds: $27.6M → $15.9M (-$11.7M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$41.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.33K |
| 4 |
Morgan Stanley
New York
|
+$848 |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$58 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$477K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$389K |
| 3 |
EP
Eversept Partners
New York
|
-$168K |
| 4 |
V
Veritable
Wilmington,
Delaware
|
-$130K |
| 5 |
Two Sigma Advisers
New York
|
-$119K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWM
26
Spire Wealth Management
Mclean,
Virginia
| $1K | -$1.07K | -350 | -41% |
|
27
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$601 | -197 | -33% |
|
|
IA
28
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
V
29
Veritable
Wilmington,
Delaware
| – | -$130K | -33,092 | Closed |
|
30
Envestnet Asset Management
Chicago,
Illinois
| – | -$66K | -16,726 | Closed |
|
31
Millennium Management
New York
| – | -$47K | -11,951 | Closed |
|
32
Simplex Trading
Chicago,
Illinois
| – | -$4.22K | -1,384 | -83% |
|
33
Wells Fargo
San Francisco,
California
| – | +$12 | +4 | +5% |
|
|
CSS
34
Cubist Systematic Strategies
Stamford,
Connecticut
| – | +$58 | +19 | New |
|
ELDN Hedge Fund Activity: Q2 2022 in Review
31 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2022, worth a combined $15.9M — down 42% from $27.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ELDN and 2 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $41.8K. The largest seller was Woodline Partners, cutting an estimated $477K.
- 31 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2022, down from 32 in Q1 2022.
- Funds reported $15.9M of Eledon Pharmaceuticals stock for Q2 2022, down 42% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q2 2022 and 3 closed out, a net change of -1 holder.
- The largest Eledon Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $41.8K added.
- The largest Eledon Pharmaceuticals seller in Q2 2022 was Woodline Partners, an estimated $477K sold.
Based on aggregated 13F filings for Q2 2022.